



BAVARIAN NORDIC

Company Announcement

October 31, 2014

Total number of voting rights and share capital in Bavarian Nordic A/S

KVISTGAARD, Denmark, October 31, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces that pursuant to section 6 of Executive Order no. 1442 of December 13, 2013 on Issuers' Disclosure Obligations, the total nominal value of Bavarian Nordic A/S' share capital is DKK 274,448,470 at the end of October 2014, which is made up of 27,444,847 shares of a nominal value of DKK 10 each, corresponding to 27,444,847 votes.

Contacts

Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47 43

Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654

About Bavarian Nordic

Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC[®], an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial, and IMVAMUNE[®], a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX[®]. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit www.bavarian-nordic.com.